Merck & Co. (MRK) Releases Earnings Results, Beats Expectations By $0.02 EPS

Merck & Co. (MRK) reported quarterly earnings results on Friday, Jul-29-2016. The company said it had a profit of $0.93 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $0.91. The company posted revenue of $9844.00 million in the period, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Merck & Co. closed down -0.17 points or -0.29% at $58.43 with 72,87,212 shares getting traded on Thursday. Post opening the session at $58.52, the shares hit an intraday low of $58.1061 and an intraday high of $58.59 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

In a different news, on Jul 5, 2016, Weir Mirian M Graddick (Exe V-P, HR) sold 45,000 shares at $57.96 per share price. According to the SEC, on Jul 5, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 60,000 shares at $58.00 per share price. On Jul 1, 2016, Adam H Schechter (EVP & Pres-Global Human Health) sold 50,000 shares at $57.69 per share price, according to the Form-4 filing with the securities and exchange commission.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Merck & Co.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.